Market Intelligence, Clinical Progress, and High-Purity Reagents for Alternative Splicing Modulation in Oncology and Neurodegeneration.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CLK1 (CDC-like Kinase 1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLK1 Kinase Domain (Active) Recombinant Protein (WT & Drug-Resistant Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW. HEK293 Expressed (active kinase). |
View CLK1 Products |
| Gene Delivery | CLK1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cellular splicing assays. CMV promoter, Puromycin selection. |
View CLK1 Products |
| Benchmark Ab | Anti-CLK1 Monoclonal Antibody (Research Grade) Recombinant positive control for Western Blot, IP, and ICC. |
View CLK1 Products |
| Validator | CLK1 siRNA Set For knockdown verification and specificity checks. Sequence verified. |
View CLK1 Products |
| Related Target A | CLK2 Close paralog (62% identity) for selectivity counter-screening and isoform-specificity assays. |
View CLK2 Products |
| Related Target B | DYRK1A Structural homolog and dual-pathway synergistic target; key off-target for safety assessment. |
View DYRK1A Products |
| Related Target C | SRPK1 Synergistic splicing kinase for combination therapy and pathway analysis. |
View SRPK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (vs CLK2/3/4) | CLK Family Panel (CLK1/2/3/4) available with >95% purity, sequence verified for off-target profiling |
| Drug Resistance Profiling | Gatekeeper & Activation Loop Mutant Proteins (e.g., T207I analogs) for resistance mechanism studies |
| Lack of Cellular Controls | Full-length Lentivirus and siRNA Set for orthogonal validation |
| Assay Background & Non-specific Binding | Endotoxin <1 EU/µg; High batch-to-batch consistency |
| ATP Competition Binding | Active kinase domain with confirmed ATP-binding site accessibility (theoretical) |
| Cellular Splicing Assays | Validated siRNA and ORF lentivirus included for reporter line construction |
Live CLK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLK1 therapeutics is intensifying, with major players shifting focus from broad-spectrum splicing modulators to highly selective CLK1-targeted small molecules and PROTAC degraders. Aberrant splicing is a hallmark of MYC-driven solid tumors and neurodegenerative disorders (e.g., Alzheimer's disease). As first-generation pan-CLK inhibitors encounter toxicity hurdles, the next wave of R&D is targeting drug-resistant mutant kinases and blood-brain barrier penetrant compounds. Lead indications include AML, hepatocellular carcinoma, MYC-amplified cancers, and neurodegeneration. Early-stage clinical trials are being advanced by companies such as TG Therapeutics (CLK1/2 dual inhibitor) and academic consortia. The convergence of splicing modulation with immunotherapy and the emergence of synthetic lethality mechanisms (e.g., CLK1 inhibition in SF3B1-mutant tumors) create novel combination opportunities requiring precise target engagement assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Biosplice, TG Therapeutics, Academic Consortia | Solid Tumors, AML, Neurodegeneration | Kinase Selectivity Panel (CLK1/2/3/4) with high-purity proteins; ATP competition assays |
| PROTAC / Degrader | Emerging Biotechs | MYC-amplified Cancers, Refractory Splicing-Addicted Cancers | Binary/Ternary Complex Formation assays (need high-purity CLK1 protein) |
| Covalent Inhibitors | Structure-based drug design groups | Refractory Cancers | Cysteine accessibility mutants for selectivity screening |
| RNA Therapeutics / Genetic Modulation | Various (DMD focus) | Muscular Dystrophy, Oncology, Fibrosis | Cellular Validation (Lentivirus & siRNA controls); splicing reporter assays |
Molecular Differentiation & Assay Strategy
Best-in-class CLK1 inhibitors must achieve >10-fold selectivity over CLK2 to avoid hematologic toxicity. Assay strategies include:
- Biochemical Kinase Assays: Use high-purity CLK1 WT and mutant proteins for IC50 determination and binding kinetics (SPR/ITC).
- Selectivity Counter-Screen: Parallel testing against CLK2/3/4, DYRK1A, and SRPK1 panels.
- Cellular Splicing Reporter Assays: Lentivirus-mediated overexpression and siRNA knockdown for target engagement confirmation.
- Resistance Mutant Profiling: Early screening against gatekeeper (T207) and activation loop mutants.
TarMart provides a complete toolkit: CLK family panel with >95% purity, endotoxin-controlled proteins, and cell-based tools (lentivirus, siRNA, benchmark antibodies) to address every stage of the discovery workflow.